JPMorgan Reinstates Ascendis Pharma (ASND) at Overweight
JPMorgan analyst Jessica Fye reinstates coverage on Ascendis Pharma (NASDAQ: ASND) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
